Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitis

OBJECTIVES: 5-aminosalicylate (mesalazine; 5-ASA) is an established first-line treatment for mild-to-moderate ulcerative colitis (UC). This study aimed to model the benefits of optimising 5-ASA therapy. METHODS: A decision tree model followed 10 000 newly diagnosed patients with mild-to-moderately a...

Descripción completa

Detalles Bibliográficos
Autores principales: Louis, Edouard, Paridaens, Kristine, Al Awadhi, Sameer, Begun, Jakob, Cheon, Jae Hee, Dignass, Axel U, Magro, Fernando, Márquez, Juan Ricardo, Moschen, Alexander R, Narula, Neeraj, Rydzewska, Grazyna, Freddi, Matthew J, Travis, Simon PL
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Inflammatory Bowel Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8845184/
https://www.ncbi.nlm.nih.gov/pubmed/35165124
http://dx.doi.org/10.1136/bmjgast-2021-000853

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8845184/
https://www.ncbi.nlm.nih.gov/pubmed/35165124
http://dx.doi.org/10.1136/bmjgast-2021-000853

Ejemplares similares